AAVACC – Advanced Veterinary Biologics Powered by ACM Technology

Next-Generation Solutions for Animal Health

AAVACC develops breakthrough immunotherapies , and next-generation vaccines, for livestock and companion animals using our proprietary Artificial Cell Membrane (ACM) polymersome delivery platform.

Our technology delivers targeted antigens with enhanced immune activation, providing superior protection while maintain exceptional safety profiles. By mimicking natural cellular processes, ACM polymersomes enable precise immune modulation that improves animal health outcomes and reduces treatment costs.

Whether you’re exploring new animal-health technologies, seeking co-development partners, or evaluating platform-based veterinary biologics — AAVACC is ready to collaborate.

Interested in partnering?

About AAVACC

Advancing Veterinary Medicine Through Synthetic Biology

AAVACC Pte Ltd is a Singapore-based biotech company focused on developing novel medicines for animal health using ACM polymersome technology licensed from ACM Biolabs Pte Ltd.

Our mission is simple:

Bring advanced nanodelivery science to livestock medicines that protect herds, improve performance, and support sustainable farming.

Founded in 2017, AAVACC combines deep scientific expertise with industry experience to develop vaccines and immunomodulators that address some of the most economically impactful diseases in pigs, poultry and other livestock.

What We Offer

Explore collaboration or licensing opportunitie — reach out to us.

Technology – Artificial Cell Membranes (ACMs)

A Powerful Delivery Platform for Modern Veterinary Biologics

Our products use Artificial Cell Membranes (ACMs) — nanoscale polymersome vesicles that mimic biological membranes while offering superior stability and flexibility.

How ACM Technology Works

ACM vesicles are smart, synthetic carriers that can protect and deliver a wide range of biomolecules and drug molecules — from proteins and peptides to DNA, mRNA and oligonucleotides (ODN).

Their polymersome structure keeps these molecules stable and guides them exactly where they need to go, enabling targeted, efficient biological responses.

In short: ACM technology turns delicate molecules into powerful veterinary solutions.

Key Benefits for Animal Health

Robust Antigen Presentation

Stabilized, correctly folded proteins presented in an optimal immune-recognition format.

Strong B- and T-Cell Responses

Supports both humoral and cell-mediated immunity — critical for many challenging pathogens.

High Stability & Scalable Manufacturing

Synthetic polymers offer enhanced physical stability and compatibility with industrial-scale production.

Injectable or Oral Delivery Options

Versatility that allows practical, field-friendly vaccination strategies.

Want to learn how ACM technology can enhance your vaccine pipeline?

Pipeline, Services & Partnerships

Developing Innovative Solutions for High-Impact Livestock Diseases

AAVACC is advancing a pipeline of medicinal candidates targeting economically significant viral and bacterial diseases in livestock.

Our ACM technology has demonstrated safety, immunogenicity, and flexibility, making it an attractive platform for next-generation veterinary medicines.

Current Focus Areas

Viral diseases in pigs, poultry and cattles
Viral diseases in companion animals
Membrane-targeted bacterial pathogens
Due to ongoing development and regulatory steps, detailed targets remain confidential, but more information will be shared as programs advance.

Partner With Us

AAVACC actively collaborates with animal health companies to accelerate development and expand access to our proprietary technology.

Let’s discuss potential partnerships — schedule a call with us.

Services we offer:

Partners

Technology Origin – ACM Biolabs Pte Ltd

Our platform is built on the proprietary polymersome technology developed by ACM Biolabs, an internationally recognized leader in synthetic membrane science. AAVACC is the dedicated partner for applying this technology to veterinary applications.

Strategic Investors & Collaborators

AAVACC works with high-level strategic investors who support scalable and sustainable growth in the global animal health market. These partnerships strengthen our scientific roadmap and ensure alignment with real-world industry needs.

Looking to invest or collaborate on novel vaccine technologies?

The People Behind the Science

AAVACC’s leadership blends materials science, immunology, and agricultural industry expertise.

International entrepreneur and founder of the Erber Group, bringing strategic direction and industry insights.

Inventor of the ACM core intellectual property, with extensive research and product development experience across Europe and Singapore.

Responsible for translating ACM platform capabilities into veterinary health products.

Laboratory and experimental specialist supporting assays, analytics and development work.

Media or partner enquiries about our leadership? Reach out to our office.

Join AAVACC

Although we are not actively hiring at the moment, we welcome speculative applications from professionals passionate about:

Send your CV and a short introduction and tell us why you’re a great fit — we’ll keep your profile on file.

Get In Touch With Us!

Whether you’re exploring partnerships, evaluating ACM technology, or seeking innovative vaccine solutions, we’d love to hear from you.

Phone

+65 6537 7364

Address

AAVACC Pte Ltd
221 Henderson Road, #07-15
Singapore 159557